Blood NAD+ concentration

There are 13 papers on blood NAD+ concentration in aging research: 9 trials and 2 observational studies in people, 1 in cells, 1 review. The newest story, Oct 28, 2026: “Nicotinamide riboside did not improve cognition in a 12-week trial”.

Biomarker

13 papers study it5 more mention it18 findings

See all 18 papers on blood NAD+ concentration

“the linear regression curves of NAD concentration plotted against age differed between males and females (p = 0.0283)”
Blood NAD levels are reduced in very old patients hospitalized for heart failureExperimental gerontology2020doi:10.1016/j.exger.2020.111051
  • Human trial9
  • Humans2
  • Cells1

Interventions

5

Nicotinamide riboside

upin humans4

4 studies
  1. Nicotinamide riboside increases blood NAD+ concentration in humans (twofold).

    “Blood NAD+ increased twofold in the NR group.”

    Human trialblood12 weeksn = 42

    Nicotinamide riboside did not improve cognition in a 12-week trial

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  2. Nicotinamide riboside increases blood NAD+ concentration in humans (measured by dried blood spot analysis) (peak +20.7% relative to baseline).

    “NR IV appeared to promote the most robust increases in NAD+ concentration as measured by dried blood spot analyses, with peak NAD+ levels increasing by 20.7% relative to baseline”

    Human trialmeasured by dried blood spot analysisintravenous500 mg

    Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen®+ IV and NAD+ IV in healthy adults

    medRxivPreprint

  3. Nicotinamide riboside increases blood NAD+ concentration in humans (NR versus placebo) (up to 5-fold increase).

    “NR greatly augmented the blood NAD metabolome with up to 5-fold increase in blood NAD+ levels.”

    Human trialNR versus placebowhole blood1500 mg twice dailyfour weeksn = 10

    NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease

    Nature communications

  4. Nicotinamide riboside increases blood NAD+ concentration in humans (dose escalation to 1 g/day) (2.6-fold increase (95% CI 17.77 to 43.49)).

    “The target NR dose was safely achieved as evidenced by a 2.6-fold increase in blood NAD+ in the NR group”

    Human trialdose escalation to 1 g/dayblood1 g/day10 weeks

    A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment

    GeroScience

More on Nicotinamide riboside

Nicotinamide mononucleotide

upin humans4

4 studies
  1. Nicotinamide mononucleotide increases blood NAD+ concentration in humans (hospitalized patients with COVID-19 and AKI) (16.0 ± 6.9 μg/mL at baseline to 42.6 ± 25.6 μg/mL at day 14).

    “MIB-626 treatment significantly but gradually raised blood NAD+ levels to a peak between 5 to 14 days”

    Human trialhospitalized patients with COVID-19 and AKIMIB-626 tablets1.0 g twice daily14 days

    Oral MIB-626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial

    FASEB bioAdvances

  2. Nicotinamide mononucleotide increases blood NAD+ concentration in humans (NMN supplementation).

    “The sensors captured the blood NAD+ increase induced by NMN supplementation”

    Human trialNMN supplementationblood

    Ratiometric NAD⁺ Sensors Reveal Subcellular NAD⁺ Modulators

    ACS sensors

  3. Nicotinamide mononucleotide increases blood NAD+ concentration in humans (statistically significant increase vs placebo and baseline; highest at 600 and 900 mg).

    “Blood NAD concentrations were statistically significantly increased among all NMN-treated groups at day 30 and day 60 when compared to both placebo and baseline (all p ≤ 0.001).”

    Human trialblood300, 600, or 900 mg daily60 daysn = 80

    The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial

    GeroScience

  4. Nicotinamide mononucleotide increases blood NAD+ concentration in humans.

    “Random-effects meta-analyses found an overall significant effect of NMN supplementation in elevating blood NAD levels.”

    Review

    Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials

    Critical reviews in food science and nutrition

More on Nicotinamide mononucleotide

NAD+ augmentation therapy

downin humans1upin humans1

1 study
  1. NAD+ augmentation therapy decreases blood NAD+ concentration in humans after treatment discontinuation.

    “declined with similarly slow kinetics following treatment discontinuation”

    Human trialafter treatment discontinuationoral NAD precursorsbloodn = 6

    The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation

    iScience

  2. NAD+ augmentation therapy increases blood NAD+ concentration in humans.

    “Blood NAD increased slowly, plateauing after approximately two weeks of treatment”

    Human trialoral NAD precursorsblood1,200 mg/dayapproximately two weeks to plateaun = 6

    The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation

    iScience

More on NAD+ augmentation therapy

Nicotinic acid

upin humans1

1 study
  1. Nicotinic acid increases blood NAD+ concentration in humans (healthy individuals) (4-6-fold).

    “High-dose nicotinic acid, a B3 vitamin, resulted in 4-6-fold increase of blood NAD+ in healthy individuals”

    Human trialhealthy individualswhole bloodhigh-dose

    Dynamics of blood NAD and glutathione in health, disease, aging, and under NAD⁺-booster treatment

    Redox biology

More on Nicotinic acid

Niacin

upin humans1

1 study
  1. Niacin increases blood NAD+ concentration in patients and matched controls (up to 8-fold).

    “Blood NAD+ increased in all subjects, up to 8-fold”

    Human trialin patients and matched controlsbloodincreasing to 750-1,000 mg/day10 months in patients, 4 months in controls

    Niacin Cures Systemic NAD⁺ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy

    Cell metabolism

More on Niacin

Upstream

1

Parkinson's disease

no changein humans1

1 study
  1. Parkinson's disease showed no clear effect on blood NAD+ concentration in humans (NAD augmentation response).

    “were not influenced by disease status or sex”

    Human trialNAD augmentation responseoral NAD precursorsblood1,200 mg/dayn = 6

    The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation

    iScience

More on Parkinson's disease

Associations

4

Heart failure

downin humans2

2 studies
  1. Heart failure is associated with blood NAD+ concentration in humans (NYHA stage II and III heart failure versus control subjects) (13 μM (min 9, max 18) versus 18 μM (minimum 15, max 23) in controls).

    “the blood levels of NAD+ (13 μM, min 9, max 18) are lower than those in the control subjects (p < 0.0001)”

    HumansNYHA stage II and III heart failure versus control subjectswhole bloodn = 24

    Efficient Assay and Marker Significance of NAD⁺ in Human Blood

    Frontiers in medicine

  2. Heart failure is associated with blood NAD+ concentration in geriatric patients hospitalized for decompensated heart failure (20.7 vs 23.4 μmol/L in healthy donors).

    “The mean concentration of NAD in whole blood samples of the geriatric population was 20.7 (SD 3.6) μmol/L (p = 0.007 versus the healthy blood donor population).”

    Humansin geriatric patients hospitalized for decompensated heart failurewhole bloodn = 19

    Blood NAD levels are reduced in very old patients hospitalized for heart failure

    Experimental gerontology

More on Heart failure

Demyelinating neurological diseases

downin humans1

1 study
  1. Demyelinating neurological diseases are associated with blood NAD+ concentration in humans (demyelinating neurological diseases versus control subjects) (14 μM (min 13, max 16) versus 18 μM (minimum 15, max 23) in controls).

    “the NAD+ levels significantly (p < 0.0001) decrease (to 14 μM, min 13, max 16), compared to the control group.”

    Humansdemyelinating neurological diseases versus control subjectswhole bloodn = 10

    Efficient Assay and Marker Significance of NAD⁺ in Human Blood

    Frontiers in medicine

More on Demyelinating neurological diseases

Age

downin humans1

1 study
  1. Age is associated with blood NAD+ concentration in humans (trend in males only; not observed in females).

    “the linear regression curves of NAD concentration plotted against age differed between males and females (p = 0.0283)”

    Humanstrend in males only; not observed in femaleswhole bloodmalesn = 151

    Blood NAD levels are reduced in very old patients hospitalized for heart failure

    Experimental gerontology

Gulf War illness

downin humans1

1 study
  1. Blood NAD+ concentration is associated with Gulf War illness in humans (pilot study comparing GWI veterans with healthy GW veterans).

    “we observed that blood nicotinamide adenine dinucleotide (NAD) and sirtuin 1 (Sirt1) protein levels were decreased in the blood of veterans with GWI compared to healthy GW veterans”

    Humanspilot study comparing GWI veterans with healthy GW veteransbloodn = 43

    Targeting sirtuin activity with nicotinamide riboside reduces neuroinflammation in a GWI mouse model

    Neurotoxicology

More on Gulf War illness

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 1Aug 2026: 1Sep 2026: 2Oct 2026: 1Nov 2026: 06 papers in 12 months
Alzheimer's & Dementia

Nicotinamide riboside did not improve cognition in a 12-week trial

In a 12-week randomized trial, supplementation doubled blood nicotinamide adenine dinucleotide from baseline but did not improve cognition or total brain blood flow…In a 12-week randomized trial, supplementation doubled blood nicotinamide adenine dinucleotide from baseline but did not improve cognition or total brain blood flow versus placebo.

Randomized trial · 42 peopleNicotinamide riboside

See all 18 papers on blood NAD+ concentration